Skip to content
Menu

Generate Biomedicines, Inc. GENB

Full chart Compare
Set alert

Price alert · GENB

All alert types
9.54 USD -0.83 (-8.00%)

Regular-session close

9.46 -0.08 -0.84%

After hours · Nov 20, 4:46 PM ET

9.40 Day range 10.58
9.40 52-week range 22.67
YTD
-24.58%
1 year
-24.58%

5D -1.81 (-14.85%)

10111213ThuFriMonTueWed10.38
Market cap
1.23B
Revenue (ttm)
21.07M
EPS (ttm)
-2.49
Shares out
129.10M
Forward P/E
-3.82
YTD return
-24.58%
1-year return
-24.58%
50-day average
13.91
200-day average
13.95
Volume
967.20K
Avg volume
1.24M
Open
10.06
Previous close
10.37
Day's range
9.40 – 10.58
52-week range
9.40 – 22.67
Analysts
Strong Buy
Price target
26.80 (+180.9%)
Earnings date
Feb 11, 2027

Key statistics

Enterprise value
1.01B
Price / sales
58.45
Price / book
3.23
Revenue growth
-56.20%
Total cash
404.21M
Total debt
75.34M
Short % of float
12.03%

Fundamental scorecard

3 of 25 checks passed on GENB’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth No data
  • Profitability No data
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
GENB Revenue — quarterly 4.22M
GENB Net income — quarterly -87.66M
GENB EPS — quarterly -0.68

Earnings

GENB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 11, 2027Dec 30, 2026-0.70667———
Nov 12, 2026Sep 30, 2026-0.55667-0.68-0.12-22.15%
Aug 6, 2026Jun 30, 2026-0.50833-0.52-0.01-2.30%

Upgrades / downgrades

GENB analyst upgrades and downgrades
DateFirmActionFromTo
Nov 18, 2026Morgan StanleymainOverweightOverweight
Oct 5, 2026HC Wainwright & Co.reitBuyBuy
Sep 8, 2026HC Wainwright & Co.reitBuyBuy
Aug 28, 2026HC Wainwright & Co.mainBuyBuy
May 14, 2026Morgan StanleymainOverweightOverweight
May 8, 2026HC Wainwright & Co.mainBuyBuy

About Generate Biomedicines, Inc.

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on GENB — it syncs with the Stock Master app.

Insider holders

GENB insider holders
InsiderRelationLatest transactionDateShares held
AFEYAN NOUBAR BOGHOSDirector and Beneficial Owner of more than 10% of a Class of SecurityPurchaseMar 1, 20260
ARNOLD FRANCES H PH.D.DirectorSaleOct 28, 2026452,535
BANCEL STEPHANE JDirectorConversion of Exercise of derivative securityMar 1, 20260
GROUS BETHOfficerPurchaseMar 1, 20260
MENDILLO JANE L.DirectorPurchaseMar 1, 20261,500
NALLY MICHAELChief Executive OfficerPurchaseMar 3, 20262,889,150

Institution ownership

GENB institution ownership
Holder% heldSharesValueReported
Flagship Pioneering LLC48.55%62,673,117597.90MSep 29, 2026
FMR, LLC5.57%7,186,20368.56MSep 29, 2026
Capital World Investors3.25%4,201,99040.09MSep 29, 2026
Braidwell LP 2.29%2,962,24928.26MSep 29, 2026
JPMORGAN CHASE & CO2.06%2,654,81025.33MSep 29, 2026
Deep Track Capital, Lp1.94%2,507,44923.92MSep 29, 2026

Fund ownership

GENB fund ownership
Holder% heldSharesValueReported
SmallCap World Fund Inc2.91%3,752,63035.80MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund1.91%2,462,99223.50MSep 29, 2026
ARK ETF Trust-ARK Genomic Revolution ETF1.26%1,628,67115.54MOct 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund0.63%816,8767.79MJun 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund0.59%763,6907.29MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF0.49%636,8046.08MSep 29, 2026